Tarsus Reports Strong Q1 2026 Results with 85%+ XDEMVY Sales Growth and Reduced Net Loss
TARS sits 60% above its 52-week low of $38.51.
Summary
Tarsus Pharmaceuticals reported strong first-quarter 2026 financial results, driven by over 85% year-over-year growth in XDEMVY net product sales and a significant reduction in net loss, while reaffirming its full-year 2026 sales guidance.
Key Events · Earnings and Guidance · TARS
-
Strong Q1 2026 Financial Performance
Reported net product sales of $145.4 million for XDEMVY, an increase of over 85% year-over-year, and significantly reduced net loss to $7.0 million from $25.1 million in the prior year period.
-
Reaffirmed Full-Year Guidance
Reaffirmed full-year 2026 guidance for XDEMVY net product sales of $670-700 million, with peak sales potential exceeding $2 billion.
-
International Expansion & Milestone
Achieved regulatory approval for XDEMVY in the People's Republic of China, triggering a $15 million milestone payment to Tarsus.
-
Pipeline Advancement
Initiated the Phase 2 Calliope trial for TP-05 (Lyme disease prevention) and continued progress on the Phase 2 trial for TP-04 (ocular rosacea), with topline data for both expected in the first half of 2027.
Analysis · TARS · Life Sciences
This 8-K filing, reporting first-quarter 2026 financial results, indicates robust commercial execution and a strengthening financial position for Tarsus Pharmaceuticals. The substantial year-over-year growth in XDEMVY sales, coupled with a significant reduction in net loss, demonstrates strong operational leverage and progress towards profitability. The reaffirmation of ambitious full-year sales guidance and the achievement of an international regulatory milestone further bolster investor confidence in the company's growth trajectory and market expansion strategy. Continued advancement of its pipeline, particularly with two Phase 2 programs, provides additional long-term value drivers. Investors should monitor the continued commercial uptake of XDEMVY and upcoming pipeline data readouts.
At the time of this filing, TARS was trading at $61.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $38.51 to $85.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.